Literature DB >> 15297153

Why study transport of peptides and proteins at the neurovascular interface.

Weihong Pan1, Abba J Kastin.   

Abstract

The blood-brain barrier (BBB) is an immense neurovascular interface. In neurodegenerative, ischemic, and traumatic disorders of the central nervous system (CNS), the BBB may hinder the delivery of many therapeutic peptides and proteins to the brain and spinal cord. Fortunately, the mistaken dogma that peptides and proteins do not cross the BBB has been corrected during the past two decades by the accumulating evidence that peptides and proteins in the periphery exert potent effects in the CNS. Not only can peptides and proteins serve as carriers for selective therapeutic agents, but they themselves may directly cross the BBB after delivery into the bloodstream. Their passage may be mediated by simple diffusion or specific transport, both of which can be affected by interactions in the blood compartment (outside the BBB) and within the endothelial cells (at the BBB level). Although the majority of current delivery strategies focuses on modification of the molecule to be delivered, understanding the mechanisms of transport will eventually facilitate regulation of the BBB directly. We review the different aspects of interactions and discuss recent advances in the cell biology of peptide/protein transport across the BBB. Better understanding of the nature and regulation of the transport systems at the BBB will provide a new direction to enhance the interactions of peripheral peptides and proteins with the CNS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297153     DOI: 10.1016/j.brainresrev.2004.04.006

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  9 in total

Review 1.  Concepts for biologically active peptides.

Authors:  Abba J Kastin; Weihong Pan
Journal:  Curr Pharm Des       Date:  2010-10       Impact factor: 3.116

2.  Characteristics of substance P transport across the blood-brain barrier.

Authors:  Arvind K Chappa; Kenneth L Audus; Susan M Lunte
Journal:  Pharm Res       Date:  2006-06-01       Impact factor: 4.200

Review 3.  Adipokines and the blood-brain barrier.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

4.  Calcitonin gene-related peptide antagonism attenuates the haemodynamic and glycaemic responses to acute hypoxaemia in the late gestation sheep fetus.

Authors:  A S Thakor; M R Bloomfield; M Patterson; D A Giussani
Journal:  J Physiol       Date:  2005-04-28       Impact factor: 5.182

Review 5.  Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation.

Authors:  Satya P Kalra
Journal:  Peptides       Date:  2009-08-06       Impact factor: 3.750

6.  Affinity peptide developed by phage display selection for targeting gastric cancer.

Authors:  Wen-Jie Zhang; Yan-Xia Sui; Arun Budha; Jian-Bao Zheng; Xue-Jun Sun; Ying-Chun Hou; Thomas D Wang; Shao-Ying Lu
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

Review 7.  Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions.

Authors:  Satya P Kalra
Journal:  Peptides       Date:  2007-10-24       Impact factor: 3.750

Review 8.  Blood-brain barrier and retroviral infections.

Authors:  Florence Miller; Philippe V Afonso; Antoine Gessain; Pierre-Emmanuel Ceccaldi
Journal:  Virulence       Date:  2012-03-01       Impact factor: 5.882

9.  Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library.

Authors:  Bo Tang; Zhexu Li; Dingde Huang; Lei Zheng; Qianwei Li
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.